ObsEva, a clinical stage biotech developing therapies for women's reproductive health and pregnancy, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Geneva, Switzerland-based company was founded in 2012. It plans to list on the Nasdaq under the symbol OBSV. Credit Suisse, Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
